The site of apalutamide in the treatment of prostate cancer Letter to the Editor

Main Article Content

Kajetan Juszczak
Tomasz Drewa

Abstract

Apalutamide belongs to the ARTA group. This drug is a new generation selective androgen receptor inhibitor. Patients with prostate cancer develop resistance to castration testosterone levels over time during hormone therapy. Therefore, it is necessary to consider additional therapeutic options based on drugs from the ARTA group. The article presents the role of apalutamide in the treatment of prostate cancer and its effectiveness. Moreover, attention was drawn to the need for close cooperation between the urologist and the oncologist in order to optimize the treatment of a patient with progressive prostate cancer.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Juszczak K, Drewa T. The site of apalutamide in the treatment of prostate cancer. OncoReview [Internet]. 2021Sep.22 [cited 2022Oct.3];11(4 (44):120-2. Available from: https://www.journalsmededu.pl/index.php/OncoReview/article/view/1725
Section
SUPPORTIVE CARE IN ONCOLOGY

References

1. Mottet N, Cornford P, van den Bergh RCN et al. (2021). EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. http://uroweb.org/guideline/prostate-cancer (access: 8.09.2021).
2. Hong JH, Kim IY. Nonmetastatic castration-resistant prostate cancer. Korean J Urol. 2014; 55(3): 153-60.
3. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65(11): 1180-92.
4. Smith MR, Saad F, Chowdhury S et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021; 79(1): 150-8.
5. Smith MR, Saad F, Chowdhury S et al; SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378(15): 1408-18.